Pubblicazioni e Impact factor
L’attività di ricerca dell’Istituto si caratterizza per una costante crescita nell’ultimo decennio, sia nel numero di pubblicazioni che nel valore di Impact Factor Normalizzato, indice bibliometrico creato dal Ministero della Salute per poter distribuire in modo equo i fondi di ricerca agli IRCCS.
Nel corso del 2020 in particolare la performance scientifica dello IOV ha avuto una netta impennata, complici diversi fattori: la nascita di nuove strutture nella sede di Castelfranco Veneto, la costituzione di gruppi di ricerca più solidi, l’aumento di pubblicazioni con autrici e autori in posizione rilevante, diversi lavori di ricerca editi su riviste ad alto impatto nella comunità scientifica. Nel 2024 c’è stata una leggera diminuzione del numero di pubblicazioni (-1,44%) a fronte però di un
incremento del IF normalizzato (+2,52%), rispetto all’anno precedente.
| Anno RC | N° pubblicazioni | IF normalizzato | IF per ricercatore | IF per ricercatore con pubblicazioni |
|---|---|---|---|---|
| 2024 | 342 | 1.958,42 | 4,02 | 8,29 |
| 2023 | 347 | 1.910,28 | 4,93 | 8,26 |
| 2022 | 302 | 1.761,87 | 4,98 | 8,69 |
Migliori pubblicazioni 2024
| Titolo | Autori | Rivista | IF grezzo |
|---|---|---|---|
| Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial | Eric Baudin, Bernard Goichot, Alfredo Berruti, Julien Hadoux, Salma Moalla, Sandrine Laboureau, Svenja Nölting, Christelle De La Fouchardière, Tina Kienitz, Timo Deutschbein, Zovato Stefania, Laurence Amar, Magalie Haissaguerre, Henri Timmers, Patricia Niccoli, Antongiulio Faggiano, Moussa Angokai, Livia Lamartina, Florina Luca, Deborah Cosentini, Stefanie Hahner, Felix Beuschlein, Marie Attard, Matthieu Texier, Martin Fassnacht, Christine Docao, Delphine Drui, Francoise Borson Chazot, Olivier Chabre, Delphine Vezzosi, Frederic Castinetti, Jérôme Bertherat, Rossella Libé, Anne Paule Gimenez-Roqueplo, Judith Favier, Marcus Quinkler, Christian Strasburger, Katrin Zopf, Martin Reincke, Matthias Kroiss, Hanna Remde, Michaela Haaf, Carmina T Fuß, Ulrich Dischinger, Graeme Eisenhofer, Christina Pamporaki, Anouk Van Berkel | LANCET | 98,40 |
Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer | Thierry Andre, Elena Elez, Eric Van Cutsem, Lars Henrik Jensen, Jaafar Bennouna, Guillermo Mendez, Michael Schenker, Christelle De La Fouchardiere, Maria Luisa Limon, Takayuki Yoshino, Jin Li, Heinz-Josef Lenz, Jose Luis Manzano Mozo, Giampaolo Tortora, Rocio Garcia-Carbonero, Laetitia Dahan, Myriam Chalabi, Rohit Joshi, Eray Goekkurt, Maria Ignez Braghiroli, Timucin Cil, Elvis Cela, Tian Chen, Ming Lei, Matthew Dixon, Sandzhar Abdullaev, Lonardi Sara | NEW ENGLAND JOURNAL OF MEDICINE | 96,30 |
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma | Kohei Shitara, Manish A. Shah, Florian Lordick, Eric Van Cutsem, David H. Ilson, Samuel J. Klempner, Yoon-Koo Kang, Lonardi Sara, Yi-Ping Hung, Kensei Yamaguchi, Peter Enzinger, Tomoko Nakajima, Maria Matsangou, Ying Cao, Ran Li, Diarmuid Moran, Rupesh Pophale, Mok Oh, Radhika Ranganath, Jaffer A. Ajani, Rui-Hua Xu | NEW ENGLAND JOURNAL OF MEDICINE | 96,30 |
Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain | Dieci Maria Vittoria, Guarneri Valentina | NATURE | 81,10 |
Defining myeloid-derived suppressor cells | Leila Akkari, Ido Amit, Bronte Vincenzo, Zvi G. Fridlender, Dmitry I. Gabrilovich, Florent Ginhoux, Catherine C. Hedrick, Suzanne Ostrand-Rosenberg | NATURE REVIEWS IMMUNOLOGY | 67,70 |
The roles of arginases and arginine in immunity | Cane’ Stefania, Roger Geiger, Bronte Vincenzo | NATURE REVIEWS IMMUNOLOGY | 67,70 |
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer | Roberto A. Leon-Ferre, Sarah Flora Jonas, Roberto Salgado, Sherene Loi, Vincent De Jong, Jodi M. Carter, Torsten O. Nielsen, Samuel Leung, Nazia Riaz, Stephen Chia, Gérôme Jules-Clément, Giuseppe Curigliano, Carmen Criscitiello, Vincent Cockenpot, Matteo Lambertini, Vera J. Suman, Barbro Linderholm, John W. M. Martens, Carolien H. M. Van Deurzen, A. Mieke Timmermans, Tatsunori Shimoi, Shu Yazaki, Masayuki Yoshida, Sung-Bae Kim, Hee Jin Lee, Dieci Maria Vittoria, Guillaume Bataillon, Anne Vincent-Salomon, Fabrice André, Marleen Kok, Sabine C. Linn, Matthew P. Goetz, Stefan Michiels | JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 63,50 |
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer | M. Ambrosini, B. Rousseau, P. Manca, O. Artz, A. Marabelle, T. André, G. Maddalena, G. Mazzoli, Intini Rossana, R. Cohen, A. Cercek, N.H. Segal, L. Saltz, A.M. Varghese, R. Yaeger, M. Nusrat, Z. Goldberg, G.Y. Ku, I. El Dika, O. Margalit, A. Grinshpun, P. Murtaza Kasi, R. Schilsky, A. Lutfi, E. Shacham-Shmueli, M. Khan Afghan, L. Weiss, C.B. Westphalen, V. Conca, B. Decker, G. Randon, E. Elez, M. Fakih, A.B. Schrock, C. Cremolini, P. Jayachandran, M.J. Overman, Lonardi Sara, F. Pietrantonio | ANNALS OF ONCOLOGY | 56,70 |
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers | Arecco L., Bruzzone M., Bas R., Kim H.J., Di Meglio A., Bernstein-Molho R., Hilbers F.S., Pogoda K., Carrasco E., Punie K., Bajpai J., Agostinetto E., Lopetegui-Lia N., Partridge A.H., Phillips K.A., Toss A., Rousset-Jablonski C., Curigliano G., Renaud T., Ferrari A., Paluch-Shimon S., Fruscio R., Cui W., Wong S.M., Vernieri C., Couch F.J., Dieci Maria Vittoria, Matikas A., Rozenblit M., Aguilar-Y Méndez D., De Marchis L., Puglisi F., Fabi A., Graff S.L., Witzel I., Rodriguez Hernandez A., Fontana A., Pesce R., Duchnowska R., Pais H.L., Sini V., Sokolovi? E., De Azambuja E., Ceppi M., Blondeaux E., Lambertini M. | ANNALS OF ONCOLOGY | 56,70 |
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO | A. Raimondi, Lonardi Sara, Murgioni Sabina, G. G. Cardellino, S. Tamberi, A. Strippoli, F. Palermo, G. De Manzoni, M. Bencivenga, A. Bittoni, C. Chiodoni, D. Lorenzini, K. Todoerti, P. Manca, S. Sangaletti, M. Prisciandaro, G. Randon, F. Nichetti, Bergamo Francesca, S. Brich, A. Belfiore, A. Bertolotti, D. Stetco, A. Guidi, T. Torelli, A. Vingiani, R. P. Joshi, M. Khoshdeli, N. Beaubier, M .C. Stumpe, Nappo Floriana, A. G. Leone, C. C. Pircher, G. Leoncini, G. Sabella, L Airo’ Farulla, A. Alessi, F. Morano, A. Martinetti, M. Niger, M. Fassan, M. Di Maio, K. Kaneva, M. Milione, H. Nimeiri, L. Agnelli, V Mazzaferro, M. Di Bartolomeo, F. Pietrantonio | ANNALS OF ONCOLOGY | 56,70 |
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671) | C. Proto, M. Ganzinelli, S. Manglaviti, M. Imbimbo, G. Galli, M. Marabese, F. Zollo, M.F. Alvisi, M. Perrino, N. Cordua, F. Borea, F. De Vincenzo, A. Chella, S. Cappelli, E. Pardini, Z. Ballatore, A. Lucarelli, E. Ambrosini, M. Giuliano, E. Pietroluongo, C. Mulargiu, A. Fabbri, A. Prelaj, M. Occhipinti, M. Brambilla, L. Mazzeo, T. Beninato, R. Vigorito, M. Ruggirello, F.G. Greco, G. Calareso, D. Miliziano, E. Rulli, I. De Simone, V. Torri, F.G.M. De Braud, Pasello Giulia, P. De Placido, R. Berardi, I. Petrini, P. Zucali, M.C. Garassino, G. Lo Russo | ANNALS OF ONCOLOGY | 56,70 |
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma | Georgina V. Long, James Larkin, Dirk Schadendorf, Jean-Jacques Grob, Christopher D. Lao, Iván Márquez-Rodas, John Wagstaff, Céleste Lebbé, Pigozzo Jacopo, Caroline Robert, Paolo A. Ascierto, Victoria Atkinson, Michael A. Postow, Michael B. Atkins, Mario Sznol, Margaret K. Callahan, Suzanne L. Topalian, Jeffrey A. Sosman, Srividya Kotapati, Pratik K. Thakkar, Corey Ritchings, Melanie Pe Benito, Sandra Re, Samira Soleymani, F. Stephen Hodi | JOURNAL OF CLINICAL ONCOLOGY | 42,10 |
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study | Carmine Pinto, Armando Orlandi, Nicola Normanno, Evaristo Maiello, Maria A. Calegari, Lorenzo Antonuzzo, Roberto Bordonaro, Maria G. Zampino, Sara Pini, Bergamo Francesca, Giuseppe Tonini, Antonio Avallone, Tiziana P. Latiano, Gerardo Rosati, Alessio Aligi Cogoni, Alberto Ballestrero, Alberto Zaniboni, Mario Roselli, Stefano Tamberi, Carlo Barone | JOURNAL OF CLINICAL ONCOLOGY | 42,10 |
Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial from Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG) | Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez Pousa, Giovanni Grignani, Brunello Antonella, Jean-Yves Blay, Oscar Tendero, Robert Diaz Beveridge, Virginia Ferraresi, Iwona Lugowska, Sara Pizzamiglio, Paolo Verderio, Valeria Fontana, Davide Maria Donati, Elena Palassini, Roberta Sanfilippo, Giuseppe Bianchi, Alexia Bertuzzi, Carlo Morosi, Sandro Pasquali, Silvia Stacchiotti, Silvia Bagué, Jean Michel Coindre, Rosalba Miceli, Angelo Paolo Dei Tos, Paolo Giovanni Casali | JOURNAL OF CLINICAL ONCOLOGY | 42,10 |
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab with or Without Atezolizumab for Patients with Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study | Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, Lisa Salvatore, Lonardi Sara, Stefano Tamberi, Federica Marmorino, Roberto Moretto, Michele Prisciandaro, Emiliano Tamburini, Giampaolo Tortora, Alessandro Passardi, Bergamo Francesca, Alessandra Raimondi, Giuliana Ritorto, Beatrice Borelli, Veronica Conca, Clara Ugolini, Giuseppe Aprile, Lorenzo Antonuzzo, Fabio Gelsomino, Erika Martinelli, Nicoletta Pella, Gianluca Masi, Luca Boni, Jerome Galon, Chiara Cremolini | JOURNAL OF CLINICAL ONCOLOGY | 42,10 |
Migliori pubblicazioni 2023
| Titolo | Autori | Rivista | IF grezzo |
|---|---|---|---|
| Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma | Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni Vanna, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D. | The New England Journal of Medicine | 74.699 |
| Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer | Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno Laura, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. | The New England Journal of Medicine | 74.699 |
| Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte Pierfranco, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. | The New England Journal of Medicine | 74.699 |
| Cancer and COVID-19: what do we really know? | Poortmans,P. M., Guarneri Valentina, Cardoso,M. -J | Lancet | 60.392 |
| Reprogramming normal cells into tumour precursors requires ECM stiffness and oncogene-mediated changes of cell mechanical properties | Panciera T, Citron A, Di Biagio D, Battilana G, Gandin A, Giulitti S, Forcato M, Bicciato S, Panzetta V, Fusco S, Azzolin L, Totaro A, Dei Tos AP, Fassan M, Vindigni V, Bassetto F, Rosato Antonio, Brusatin G, Cordenonsi M, Piccolo S. | Nature Materials | 38.663 |
| A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation | Prat,A., Guarneri Valentina, Parè,L., Griguolo Gaia, Pascual,T., Dieci Maria Vittoria, Chic,N., Gonzalez-Farrè,B., Frassoldati,A., Sanfeliu,E., Cejalvo,J. M., Munoz,M., Bisagni,G., Braso-Maristany,F., Urso,L., Vidal,M., Brandes,A. A., Adamo,B., Musolino,A., MIGLIETTA FEDERICA (…) | Lancet Oncology | 33.752 |
| A new standard of care for patients with high-risk rhabdomyosarcoma? – Authors’ reply | Bisogno,G., Ferrari,A., Melcon,S. G., De Salvo Gian Luca, Bergeron,C., Jenney,M. | Lancet Oncology | 33.752 |
| Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial | Dummer,R., Brase,J. C., Garrett,J., Campbell,C. D., Gasal,E., Squires,M., Gusenleitner,D., Santinami,M., Atkinson,V., Mandalà ,M., Chiarion-Sileni Vanna, Flaherty,K., Larkin,J., Robert,C., Kefford,R., Kirkwood,J. M., Hauschild,A., Schadendorf,D., Long,G. V. | Lancet Oncology | 33.752 |
| Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial | Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni Vanna, Márquez-Rodas I, Butler MO, Maio M, Middleton MR, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill A, Fecher LA, Millward M, Khushalani NI, Queirolo P, Lobo M, de Pril V, Loffredo J, Larkin J, Weber J. | Lancet Oncology | 33.752 |
| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study | Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello Giulia, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L; TERAVOLT investigators. | Lancet Oncology | 33.752 |
| Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial | Bonvalot S, Gronchi A, Le Péchoux C, Swallow CJ, Strauss D, Meeus P, van Coevorden F, Stoldt S, Stoeckle E, Rutkowski P, Rastrelli Marco, Raut CP, Hompes D, De Paoli A, Sangalli C, Honoré C, Chung P, Miah A, Blay JY, Fiore M, Stelmes JJ, Dei Tos AP, Baldini EH, Litière S, Marreaud S, Gelderblom H, Haas RL. | Lancet Oncology | 33.752 |
| Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study | Koller M, Shamieh O, Hjermstad MJ, Hornslien K, Young T, Chalk T, Ioannidis G, Harle A, Johnson CD, Tomaszewski KA, Serpentini Samantha, Pinto M, van der Weijst L, Janssens A, Morag O, Chie WC, Arraras JI, Pompili C, Jungraithmayr W, Hechtner M, Katsochi D, Müller K, Gräfenstein L, Schulz C, Bottomley A; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; EORTC Lung Cancer Group; European Society of Thoracic Surgeons. | Lancet Oncology | 33.752 |
| Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial | Cremolini C, Antoniotti C, Rossini D, Lonardi Sara, Loupakis Fotios, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni Sabina, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, Di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel Vittorina, Fontanini G, Ugolini C, Boni L, Falcone A; GONO Foundation Investigators. | Lancet Oncology | 33.752 |
Migliori pubblicazioni 2022
| Titolo | Autori | Rivista | IF grezzo |
|---|---|---|---|
| Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial | Andrea Sartore-Bianchi, Filippo Pietrantonio, Lonardi Sara, Benedetta Mussolin, Francesco Rua, Giovanni Crisafulli, Alice Bartolini, Elisabetta Fenocchio, Alessio Amatu, Paolo Manca, bergamo francesca, Federica Tosi, Gianluca Mauri, Margherita Ambrosini, Daniel Francesca, Valter Torri, Angelo Vanzulli, Daniele Regge, Giovanni Cappello, Caterina Marchiò, Enrico Berrino, Anna Sapino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli | NATURE MEDICINE | 87,24 |
| RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer | Elena Elez, Javier Ros, Jose Fernández, Guillermo Villacampa, Ana Belén Moreno-Cárdenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Intini Rossana, Montagna Aldo, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Lonardi Sara, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo | NATURE MEDICINE | 87,24 |
| Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial | Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, Aurélie Catteau, Lisa Salvatore, Lonardi Sara, Isabelle Boquet, Stefano Tamberi, Federica Marmorino, Roberto Moretto, Margherita Ambrosini, Emiliano Tamburini, Giampaolo Tortora, Alessandro Passardi, bergamo francesca, Alboukadel Kassambara, Thomas Sbarrato, Federica Morano, Giuliana Ritorto, Beatrice Borelli, Alessandra Boccaccino, Veronica Conca, Mirella Giordano, Clara Ugolini, Jacques Fieschi, Alexia Papadopulos, Clémentine Massoué, Giuseppe Aprile, Lorenzo Antonuzzo, Fabio Gelsomino, Erika Martinelli, Nicoletta Pella, Gianluca Masi, Gabriella Fontanini, Luca Boni, Jérôme Galon, Chiara Cremolini | LANCET ONCOLOGY | 54,43 |
| Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice? | Rodrigo Dienstmann, Lonardi Sara | LANCET ONCOLOGY | 54,43 |
| Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial | Paolo A. Ascierto, Mario Mandalà, Pier Francesso Ferrucci, Massimo Guidoboni, Piotr Rutkowski, Virginia Ferraresi, Ana Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F. Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M. Grimaldi, Diana Giannarelli, Reinhard Dummer, chiarion sileni vanna | JOURNAL OF CLINICAL ONCOLOGY | 50,74 |
| Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO | Daniele Rossini, Carlotta Antoniotti, Lonardi Sara, Filippo Pietrantonio, Roberto Moretto, Lorenzo Antonuzzo, Alessandra Boccaccino, Federica Morano, Marco Brugia, Carmelo Pozzo, Federica Marmorino, bergamo francesca, Emiliano Tamburini, Alessandro Passardi, Giovanni Randon, Murgioni Sabina, Beatrice Borelli, Angela Buonadonna, Mirella Giordano, Gabriella Fontanini, Veronica Conca, Vincenzo Formica, Massimo Aglietta, Roberto Bordonaro, Giuseppe Aprile, Gianluca Masi, Luca Boni, Chiara Cremolini | JOURNAL OF CLINICAL ONCOLOGY | 50,74 |
| Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial | Federica Morano, Alessandra Raimondi, Filippo Pagani, Lonardi Sara, Lisa Salvatore, Chiara Cremolini, Murgioni Sabina, Giovanni Randon, Federica Palermo, Lorenzo Antonuzzo, Nicoletta Pella, Patrizia Racca, Michele Prisciandaro, Monica Niger, Francesca Corti, bergamo francesca, Alberto Zaniboni, Margherita Ratti, Michele Palazzo, Celeste Cagnazzo, Maria Alessandra Calegari, Federica Marmorino, Iolanda Capone, Elena Conca, Adele Busico, Silvia Brich, Elena Tamborini, Federica Perrone, Massimo Di Maio, Massimo Milione, Maria Di Bartolomeo, Filippo De Braud, Filippo Pietrantonio | JOURNAL OF CLINICAL ONCOLOGY | 50,74 |
| Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials | Claire Gallois, Qian Shi, Jeffrey Meyers, Lonardi Sara, Greg Yothers, Julien Taieb | JOURNAL OF CLINICAL ONCOLOGY | 50,74 |
| Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) | Roberta Sanfilippo, Richard L. Hayward, Jammbe Musoro, Charlotte Benson, Michael Gordon Leahy, Brunello Antonella, Jean-Yves Blay, Neeltje Steeghs, Ingrid M. E. Desar, Nasim Ali, Alice Hervieu, Khin Thway, Sandrine Marreaud, Saskia Litiere, Bernd Kasper | JAMA Oncology | 33,01 |
| Autoimmune gastritis: Long-Term natural history in naïve Helicobacter pylori-negative patients | Massimo Rugge, Ludovica Bricca, Stefano Guzzinati, Diana Sacchi, Marco Pizzi, Edoardo Savarino, Fabio Farinati, Manuel Zorzi, Fassan Matteo, Angelo Paolo Dei Tos, Peter Malfertheiner, Robert M Genta, David Y Graham | GUT | 31,80 |
| A Novel Benchmarking Approach to Assess the Agreement among Radiomic Tools | Bettinelli Andrea, Marturano Francesca, Michele Avanzo, Emiliano Loi, Enrico Menghi, Emilio Mezzenga, Giovanni Pirrone, Anna Sarnelli, Lidia Strigari, Silvia Strolin, paiusco marta | RADIOLOGY | 29,15 |
| Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance | Patrizia Romani, Nunzia Nirchio, Mattia Arboit, Barbieri Vito, Tosi Anna, Federica Michielin, Soichi Shibuya, Thomas Benoist, Danchen Wu, Charles Colin Thomas Hindmarch, Monica Giomo, Anna Urciuolo, Flavia Giamogante, Antonella Roveri, Marco Montagner, Probir Chakravarty, Tito Calì, Nicola Elvassore, Stephen L. Archer, Paolo De Coppi, Rosato Antonio, Graziano Martello, Sirio Dupont | NATURE CELL BIOLOGY | 28,21 |
| Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair | Silvia Alvarez, Ana C. da Silva Almeida, Robert Albero, Mayukh Biswas, Angelica Barreto-Galvez, Thomas S. Gunning, Anam Shaikh, Tomas Aparicio, Agnieszka Wendorff, Piovan Erich, Pieter Van Vlierberghe, Steven Gygi, Jean Gautier, Advaitha Madireddy, Adolfo A. Ferrando | BLOOD | 25,67 |
| Tyd LGL leukemia identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients | G Barilà, Grassi Angela, H Cheon, G Semenzato, R Zambello | BLOOD | 25,67 |
| Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse | Chiara Rusconi, Chan Y. Cheah, Toby A. Eyre, David Tucker, Pavel Klener, Eva Giné, Lara Crucitti, Cristina Muzi, Sara Iadecola, Gabriele Infante, Sophie Bernard, Rebecca L. Auer, Chiara Pagani, Monika Duglosz-Danecka, Heidi Mocikova, Tom van Meerten, Emanuele Cencini, Ana Marin-Niebla, Michael E. Williams, Piera Angelillo, Paolo Nicoli, Annalisa Arcari, Lucia Morello, Donato Mannina, Orsola Vitagliano, Sartori Roberto, Annalisa Chiappella, Roberta Sciarra, Piero M. Stefani, Martin Dreyling, John F. Seymour, Carlo Visco | BLOOD | 25,67 |
I dati pubblicati in questa pagina sono forniti dalla Biblioteca scientifica IOV.